Nasal Sprays Archives

HIV drugs may lower COVID risk; COVID and flu co-infection raises risk of severe illness, death

Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, HIV, Hospitalized COVID-19 Patients, Influenza, Nasal Sprays, Protease inhibitors, R&D, SARS-CoV-2 virus, Small Molecules, The Lancet, Therapeutics

Certain drugs used to treat HIV may have a role in preventing SARS-CoV-2 infections, according to preliminary data that may help explain why people living with the condition have not appeared to be at higher risk for serious COVID-19 despite being generally more vulnerable to infections. Additionally, having COVID-19 and influenza at the same time puts hospitalized adults at much greater risk of critical illness and death compared to having COVID-19 without the flu, researchers reported in The Lancet.

March 28, 2022/by Reuters Health

COVID-19 Update: Therapeutic Hits and Misses and an Effective Nasal Spray

Alcohol, Alcoholism, Antivirals, Biopharma Companies, Clinical Trials, India, Lung Injuries, Nasal Sprays, Omicron (B.1.1.529) (South Africa), Paxlovid, Pfizer, R&D, Researchers, SARS-CoV-2 virus

As Pfizer’s antiviral Paxlovid tablets against COVID-19 roll out, the company indicated it had halted the development of the intravenous variation of the drug, PF-07304814. In other news, SaNOtize Research & Development Corp. and Glenmark Pharmaceuticals Ltd. announced that a Phase III trial of Nitric Oxide Nasal Spray (NONS) hit the primary endpoint.

February 9, 2022/by BioSpace

Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI

Business, Commercialization, Diabetic Gastroparesis, Gastrointestinal Disorders, Life Sciences, Marketing & Advertising, Nasal Sprays, Partnerships, Specialty Pharma, Therapeutics

Evoke Pharma Inc., a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA Life Science Service LLC, an independent provider of global commercial services to the life science industry, announced an extension of their agreement. The companies will continue collaborating on the commercialization and distribution of Gimoti (metoclopramide) nasal spray in the United States through the end of 2026.

February 2, 2022/by Andrew Humphreys

Easier-to-produce COVID vaccine shows promise in trials; nasal spray vaccine booster works in mice

Clinical Trials, COVID-19 booster shots, COVID-19 shots, COVID-19 Vaccines, Immune System, Immunity, Intranasal vaccines, Low-Income Countries, Lung Transplants, Messenger RNA (mRNA) Vaccines, Mice, Middle-Income Countries, Nasal Sprays, New England Journal of Medicine, R&D, Researchers, Yale University

A COVID-19 vaccine that can be produced locally in low-income and middle-income countries is yielding promising results in early clinical trials, researchers say. Other researchers believe that once the body has been “primed” by mRNA vaccines to recognize and attack the coronavirus, a booster containing purified versions of virus’ spike protein that could be given intranasally would have many advantages.

January 29, 2022/by Reuters Health

Nasal Vaccine Starts Trial to Protect Against Alzheimer’s

Alzheimer's Disease, Clinical Trials, Nasal Sprays, R&D, Vaccinations

Following years of preparation, scientists from Brigham and Women’s Hospital are ready to start a clinical trial that will evaluate the use of an intranasal vaccine to prevent Alzheimer’s disease (AD).

November 16, 2021/by BioSpace

Oyster Point’s drug becomes first FDA-approved nasal spray to treat dry eyes

Business, Clinical Trials, Dry Eye Disease, Nasal Sprays, R&D, Shares, Therapeutics

Oyster Point Pharma Inc.’s treatment for dry eye disease became the first U.S. approved nasal spray for the chronic condition on Oct. 18, sending the drug developer’s shares higher.

October 18, 2021/by Andrew Humphreys

Russia to test COVID-19 vaccine in form of nasal spray

Adults, Clinical Trials, Nasal Sprays, R&D, Russia, Sputnik V vaccine

Russia will test a nasal spray form of the Sputnik V vaccine against Covid-19 among adult volunteers, according to a state document published on Oct. 12, as the country struggles to rein in rising numbers of infections and deaths.

October 12, 2021/by Andrew Humphreys

Two Intranasal Candidates Get Closer to Augmenting Pandemic Response

Business, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, Covid-19 Data, Immunogenicity Data, Intranasal vaccines, Machine Learning, Nasal Sprays, R&D, SARS-CoV-2 virus

Codagenix Inc. announced favorable safety and immunogenicity data from a Phase I dose-escalation trial of the company’s single-dose intranasal COVI-VAC vaccine, and London-based pHOXBIO Ltd. reported results from a pivotal phase II/III study of the novel prophylactic nasal spray pHOXWELL.

September 22, 2021/by Andrew Humphreys

India’s Bharat Biotech’s nasal COVID-19 vaccine advances into next stage of trials

Clinical Trials, Coronavirus Cases, Covaxin (Bharat Biotech and ICMR), COVID-19 Vaccines, India, Nasal Sprays, R&D, Reuters

Indian vaccine maker Bharat Biotech’s nasal Covid-19 vaccine candidate received regulatory approval for mid-stage to late-stage trials, the government’s ministry of science and technology said in a statement on Aug. 13.

August 13, 2021/by Andrew Humphreys

FDA Accepts NDA for Oyster Point’s Dry Eye Therapy

Business, Clinical Data, Clinical Trials, Dry Eye Disease, FDA, Immunosuppressants, Nasal Sprays, New Drug Applications, R&D, Secondary Endpoints, Stocks

Oyster Point’s New Drug Application (NDA) for the dry eye disease therapy OC-01 was accepted for FDA regulatory review on the back of positive Phase III data.

March 2, 2021/by Andrew Humphreys